NCT06322342 - Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Central Nervous System (CNS) LesionsBrain MetastasesBrain NeoplasmsBrain Neoplasms, BenignBrain Tumor, PrimaryBrain Tumor, RecurrentBrain TumorsBrain CancerBrain TumorBrain Neoplasm, PrimaryMultiple SclerosisMultiple Sclerosis Brain LesionNeurofibromaAcoustic NeuromaCNS TumorCNS LesionCNS MetastasesCNS CancerCNS LymphomaVon Hippel LindauMeningiomaGliomaSchwannomasNeuroinflammationNeoplasia

Interventions

DRUG

RVP-001

MRI contrast agent

Trial Locations (5)

27710

RECRUITING

Duke University Medical Center, Durham

65212

RECRUITING

University of Missouri, Columbia

06510

RECRUITING

Yale New Haven Hospital, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston

02115

RECRUITING

Brigham & Women's Hospital, Boston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Reveal Pharmaceuticals Inc.

INDUSTRY